Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioLineRx Ltd. - American Depositary Shares (NQ: BLRX )

3.050 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioLineRx Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
Let's take a look at the stocks that are in motion in today's session.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Top stock movements in today's session.
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
There are notable gap-ups and gap-downs in today's session.
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Earnings Preview For BioLine Rx
Via Benzinga
BLRX Stock Earnings: BioLine Rx Beats Revenue for Q2 2024
BLRX stock results show that BioLine Rx beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Earnings Preview For BioLine Rx
Via Benzinga
BioLine Rx Earnings Preview
Via Benzinga
Nasdaq Surges Over 300 Points; State Street Earnings Top Views
Via Benzinga
S&P 500 Gains 1%; Fastenal Posts Downbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Jumps Over 300 Points; US Industrial Production Beats Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet
Via Benzinga
S&P Jumps 1%; Regional Health Properties Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Open Higher; Dow Jumps Over 200 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Why Check-Cap Shares Are Trading Higher By Over 52%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Scheduled For November 25, 2024
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why Arcadium Lithium Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Tuesday morning! 
Via InvestorPlace
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
These 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as the risk is real. 
Via InvestorPlace
BLRX Stock Earnings: BioLine Rx Beats EPS for Q1 2024
BLRX stock results show that BioLine Rx beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023
BLRX stock results show that BioLine Rx beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
When you want to light your afterburners, these ideas will do the trick. 
Via InvestorPlace
Earnings Scheduled For November 20, 2023
Companies Reporting Before The Bell • Greenland Technologies (NASDAQ:GTEC) is projected to report quarterly earnings at $0.05 per share on revenue of $24.26 million. 
Via Benzinga
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have... 
Via Talk Markets
3 Tech Stocks That Wall Street Loves More Than Nvidia
Purchase these top tech stocks now to achieve maximum profits and allow your portfolio to skyrocket given the volatile market. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.